Anti-Diabetic Effect of Telmisartan Through its Partial PPARγ-Agonistic Activity

Anti-Diabetic Effect of Telmisartan Through its Partial PPARγ-Agonistic Activity

Muluken Altaye Ayza, Kaleab Alemayehu Zewdie, Bekalu Amare Tesfaye, Selamawit Tesfamariam Gebrekirstos, Derbew Fikadu Berhe Department of Pharmacology and Toxicology, School of Pharmacy, Mekelle University, Mekelle, EthiopiaCorrespondence: Muluken Altaye Ayza Tel +251-916707913 Email Mulealto1@gmail...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Ayza MA, Zewdie KA, Tesfaye BA, Gebrekirstos ST, Berhe DF
Formato: article
Lenguaje:EN
Publicado: Dove Medical Press 2020
Materias:
diabetes mellitus
hypertension
peroxisome proliferator-activated receptors
telmisartan
Specialties of internal medicine
RC581-951
Acceso en línea:https://doaj.org/article/5e533ab8d45444739832511dd2413d0e
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:5e533ab8d45444739832511dd2413d0e
record_format dspace
spelling oai:doaj.org-article:5e533ab8d45444739832511dd2413d0e2021-12-02T12:51:03ZAnti-Diabetic Effect of Telmisartan Through its Partial PPARγ-Agonistic Activity1178-7007https://doaj.org/article/5e533ab8d45444739832511dd2413d0e2020-10-01T00:00:00Zhttps://www.dovepress.com/anti-diabetic-effect-of-telmisartan-through-its-partial-ppargamma-agon-peer-reviewed-article-DMSOhttps://doaj.org/toc/1178-7007Muluken Altaye Ayza, Kaleab Alemayehu Zewdie, Bekalu Amare Tesfaye, Selamawit Tesfamariam Gebrekirstos, Derbew Fikadu Berhe Department of Pharmacology and Toxicology, School of Pharmacy, Mekelle University, Mekelle, EthiopiaCorrespondence: Muluken Altaye Ayza Tel +251-916707913 Email Mulealto1@gmail.comAbstract: Telmisartan is an angiotensin II receptor antagonist, which selectively inhibits the angiotensin II type 1 receptor. Thus, it is widely used for hypertension management. Nowadays, telmisartan’s effect on peroxisome proliferator-activated receptors (PPARs) is gaining wider attention. PPARs are ligand-activated transcription factors that belong to the nuclear hormone receptor superfamily. Telmisartan is reported to have a partial PPARγ-agonistic effect while avoiding the safety concerns found with full PPARγ agonists (thiazolidinediones). Telmisartan could be an alternative treatment option, with dual benefit for diabetes mellitus (DM) and hypertension. This review summarizes the anti-diabetic activity of telmisartan via its partial PPARγ-agonistic activity.Keywords: diabetes mellitus, hypertension, peroxisome proliferator-activated receptors, telmisartanAyza MAZewdie KATesfaye BAGebrekirstos STBerhe DFDove Medical Pressarticlediabetes mellitushypertensionperoxisome proliferator-activated receptorstelmisartanSpecialties of internal medicineRC581-951ENDiabetes, Metabolic Syndrome and Obesity: Targets and Therapy, Vol Volume 13, Pp 3627-3635 (2020)
institution DOAJ
collection DOAJ
language EN
topic diabetes mellitus
hypertension
peroxisome proliferator-activated receptors
telmisartan
Specialties of internal medicine
RC581-951
spellingShingle diabetes mellitus
hypertension
peroxisome proliferator-activated receptors
telmisartan
Specialties of internal medicine
RC581-951
Ayza MA
Zewdie KA
Tesfaye BA
Gebrekirstos ST
Berhe DF
Anti-Diabetic Effect of Telmisartan Through its Partial PPARγ-Agonistic Activity
description Muluken Altaye Ayza, Kaleab Alemayehu Zewdie, Bekalu Amare Tesfaye, Selamawit Tesfamariam Gebrekirstos, Derbew Fikadu Berhe Department of Pharmacology and Toxicology, School of Pharmacy, Mekelle University, Mekelle, EthiopiaCorrespondence: Muluken Altaye Ayza Tel +251-916707913 Email Mulealto1@gmail.comAbstract: Telmisartan is an angiotensin II receptor antagonist, which selectively inhibits the angiotensin II type 1 receptor. Thus, it is widely used for hypertension management. Nowadays, telmisartan’s effect on peroxisome proliferator-activated receptors (PPARs) is gaining wider attention. PPARs are ligand-activated transcription factors that belong to the nuclear hormone receptor superfamily. Telmisartan is reported to have a partial PPARγ-agonistic effect while avoiding the safety concerns found with full PPARγ agonists (thiazolidinediones). Telmisartan could be an alternative treatment option, with dual benefit for diabetes mellitus (DM) and hypertension. This review summarizes the anti-diabetic activity of telmisartan via its partial PPARγ-agonistic activity.Keywords: diabetes mellitus, hypertension, peroxisome proliferator-activated receptors, telmisartan
format article
author Ayza MA
Zewdie KA
Tesfaye BA
Gebrekirstos ST
Berhe DF
author_facet Ayza MA
Zewdie KA
Tesfaye BA
Gebrekirstos ST
Berhe DF
author_sort Ayza MA
title Anti-Diabetic Effect of Telmisartan Through its Partial PPARγ-Agonistic Activity
title_short Anti-Diabetic Effect of Telmisartan Through its Partial PPARγ-Agonistic Activity
title_full Anti-Diabetic Effect of Telmisartan Through its Partial PPARγ-Agonistic Activity
title_fullStr Anti-Diabetic Effect of Telmisartan Through its Partial PPARγ-Agonistic Activity
title_full_unstemmed Anti-Diabetic Effect of Telmisartan Through its Partial PPARγ-Agonistic Activity
title_sort anti-diabetic effect of telmisartan through its partial pparγ-agonistic activity
publisher Dove Medical Press
publishDate 2020
url https://doaj.org/article/5e533ab8d45444739832511dd2413d0e
work_keys_str_mv AT ayzama antidiabeticeffectoftelmisartanthroughitspartialppargammaagonisticactivity
AT zewdieka antidiabeticeffectoftelmisartanthroughitspartialppargammaagonisticactivity
AT tesfayeba antidiabeticeffectoftelmisartanthroughitspartialppargammaagonisticactivity
AT gebrekirstosst antidiabeticeffectoftelmisartanthroughitspartialppargammaagonisticactivity
AT berhedf antidiabeticeffectoftelmisartanthroughitspartialppargammaagonisticactivity
_version_ 1718393625707020288

Ejemplares similares